Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label, single-arm, dose-escalation, dose-expansion study assessed t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Jain, Nitin, Stock, Wendy, Zeidan, Amer, Atallah, Ehab, McCloskey, James, Heffner, Leonard, Tomlinson, Benjamin, Bhatnagar, Bhavana, Feingold, Jay, Ungar, David, Chao, Grace, Zhang, Xiaoyan, Qin, Yajuan, Havenith, Karin, Kantarjian, Hagop, Wieduwilt, Matthew J.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2020
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013258/
https://ncbi.nlm.nih.gov/pubmed/32012214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000767
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires